Memorializing Governor Kathy Hochul to proclaim May 11-17, 2025, as Fibromyalgia Awareness Week in the State of New York
This resolution memorializes Governor Kathy Hochul to proclaim May 11-17, 2025, as Fibromyalgia Awareness Week in New York State. It is a ceremonial measure that does not create a new program, mandate, or entitlement; instead, it recognizes fibromyalgia as a chronic, often disabling condition and highlights the need for greater public awareness, research, education, and support for affected individuals.
The resolution describes fibromyalgia’s symptoms, prevalence, diagnostic delays, costs, and the challenges patients face in medical, workplace, and educational settings. It also references the work of the Fibromyalgia Task Force of New York State and related advocacy efforts, and it urges support for research into prevention, treatment, and a cure. The measure would result in the transmission of the adopted resolution to the Governor and several health and medical organizations.
Because this is a memorializing resolution, it has no direct legal effect on state statutes, regulations, or agency duties. Its practical impact is limited to official recognition and public awareness, while potentially encouraging attention from state health officials, medical institutions, employers, and advocacy groups regarding diagnosis, accommodations, and treatment of fibromyalgia.
The overall sentiment is strongly supportive and sympathetic toward people living with fibromyalgia. The resolution frames the condition as serious, underrecognized, and deserving of greater research and institutional understanding, and there is no indication of opposition in the provided record. The tone is advocacy-oriented and commemorative rather than legislative or partisan.
No formal contention appears in the available bill history, and there are no recorded votes or committee transcripts showing disagreement. The only implied points of concern are the resolution’s emphasis on gaps in medical education, delayed diagnosis, workplace accommodations, and the need for more research funding and clinical guidance, but these are presented as reasons for support rather than as disputed issues.